key: cord-1050614-ayc61jor
authors: Togashi, Yuki; Kono, Yuta; Okuma, Takashi; Shioiri, Nao; Mizushima, Reimi; Tanaka, Akane; Ishiwari, Mayuko; Toriyama, Kazutoshi; Kikuchi, Ryota; Takoi, Hiroyuki; Abe, Shinji
title: Surfactant protein D: A useful biomarker for distinguishing COVID‐19 pneumonia from COVID‐19 pneumonia‐like diseases
date: 2022-04-25
journal: Health Sci Rep
DOI: 10.1002/hsr2.622
sha: 60a25ede78f9c66eebef0ade612c4834b75015a2
doc_id: 1050614
cord_uid: ayc61jor

INTRODUCTION: Computed tomography is useful for the diagnosis of coronavirus disease (COVID‐19) pneumonia. However, many types of interstitial lung diseases and even bacterial pneumonia can show abnormal chest shadows that are indistinguishable from those observed in COVID‐19 pneumonia. Thus, it is necessary to identify useful biomarkers that can efficiently distinguish COVID‐19 pneumonia from COVID‐19 pneumonia‐like diseases. Herein, we investigated the usefulness of serum Krebs von den Lungen 6 (KL‐6) and surfactant protein D (SP‐D) for identifying patients with COVID‐19 pneumonia among patients with abnormal chest shadows consistent with COVID‐19 pneumonia. METHOD: This was a retrospective cohort study of consecutive patients who underwent evaluation of serum KL‐6 and SP‐D at a single center from February 2019 to December 2020. A total of 54 patients with COVID‐19 pneumonia and 65 patients with COVID‐19 pneumonia‐like diseases were enrolled in this study from the source population. Serum KL‐6 and SP‐D levels in both groups were analyzed. RESULT: The serum levels of KL‐6 and SP‐D in patients with COVID‐19 pneumonia were significantly lower than those in patients with COVID‐19 pneumonia‐like disease (median [interquartile range]: 208.5 [157.5–368.5] U/ml vs. 430 [284.5–768.5] U/ml, p < 0.0001 and 24.7 [8.6–51.0] ng/ml vs. 141 [63.7–243.5] ng/ml, p < 0.0001, respectively). According to receiver operating characteristic (ROC) analysis, the areas under the ROC curves (95% confidence intervals) of serum KL‐6 and SP‐D levels for distinguishing COVID‐19 pneumonia from COVID‐19 pneumonia‐like diseases were 0.761 (0.675–0.847) and 0.874 (0.812–0.936), respectively. The area under the ROC curve of serum SP‐D was significantly larger than that of serum KL‐6 (p = 0.0213), suggesting that serum SP‐D can more efficiently distinguish COVID‐19 pneumonia from COVID‐19 pneumonia‐like diseases. CONCLUSION: Serum SP‐D is a promising biomarker for distinguishing COVID‐19 pneumonia from COVID‐19 pneumonia‐like diseases. Serum SP‐D can be useful for the management of patients with abnormal chest shadow mimicking COVID‐19 pneumonia.

However, the accuracy of NAAT and antigen testing is not perfect.

False-negative results are particularly serious because they can promote virus transmission and cause nosocomial infections. Falsenegative results of NAAT are reported to occur in approximately 30% of patients with COVID-19. 1 Moreover, the accuracy of antigen tests is less than that of NAAT 2 Therefore, it is important to suspect COVID-19 by clinical presentation, isolate suspected patients and repeat NAAT or antigen testing. However, there are no clinical presentations characteristic of COVID-19. The typical symptoms of COVID-19, such as cough, fever, and fatigue, are quite common in other acute respiratory diseases, and a substantial number of patients are asymptomatic. 3 Thus, it is not easy to suspect COVID-19 solely based on clinical presentation.

Chest computed tomography (CT) is known to have high sensitivity in diagnosing COVID-19 and is used as a useful tool for the diagnosis of COVID-19 in clinical practice. 4 The typical findings of chest CT are bilateral ground-glass opacities (GGOs) and/or consolidation, predominantly located peripherally and posteriorly in the lungs. 5 However, the specificity of chest CT for diagnosing COVID-19 is low. 4 Many types of interstitial lung diseases (ILD) frequently show similar shadows on chest CT and chest CT findings of ILD are sometimes indistinguishable from those of COVID-19 pneumonia. In addition, even bacterial pneumonia can show GGOs, and bilateral or multilobar distribution is not rare. 6 Thus, when patients with negative NAAT results and abnormal chest shadow mimicking COVID-19 pneumonia are admitted to the hospital, the possibility of false-negative NAAT results must be considered. Such cases are not rare, as patients presenting bilateral GGOs and/or consolidation on chest CT are often admitted to the hospital, regardless of the etiology. Therefore, a biomarker that can distinguish COVID-19 pneumonia from COVID-19 pneumonia-like diseases is required for infection control in COVID-19 outbreak settings.

Serum surfactant protein D (SP-D) and Krebs von den Lungen 6 (KL-6) are useful biomarkers for the diagnosis and evaluation of ILD. 7, 8 Both biomarkers are reported to increase in many types of ILD, such as idiopathic pulmonary fibrosis and collagen vascular disease-related interstitial pneumonia (CVD-IP). 7 In COVID-19, serum KL-6 and SP-D levels were reported to increase in severe patients and were useful as prognostic biomarkers of severity. [9] [10] [11] [12] [13] However, their usefulness as diagnostic biomarkers remains unknown. Based on this knowledge, we addressed the usefulness of serum KL-6 and SP-D for distinguishing COVID-19 pneumonia from COVID-19 pneumonia-like diseases by evaluating serum KL-6 and SP-D levels in COVID-19 pneumonia patients and non-COVID-19 pneumonia patients whose chest CT images showed abnormal shadows mimicking COVID-19 pneumonia on retrospective analysis. 

Variables are presented as medians and interquartile range (IQR).

Statistical significance was set at p < 0.05. Categorical variables were compared using Fisher's exact test. Kruskal-Wallis test and Mann-Whitney U test were performed to analyze the differences between the selected groups. Serum SP-D and KL-6 levels below the lower detection limit were given half the limit's value.

Multivariable logistic regression analysis and receiver operating characteristic (ROC) analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan). The areas under the ROC curves were compared using the DeLong test. In multivariable logistic regression analysis, the diagnosis of COVID-19 was used as a dependent variable, whereas age, sex, serum KL-6 level, serum SP-D level, and cancer were used as independent variables. All other statistical analyses were performed using GraphPad Prism software (GraphPad, San Diego, CA). pneumonia-like diseases (7 [4] [5] [6] [7] [8] [9] days vs. 10 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Other patients were diagnosed with pneumocystis pneumonia (n = 3), diffuse alveolar hemorrhage (n = 2), radiation pneumonitis (n = 1), eosinophilic pneumonia (n = 1), and intravascular lymphoma (n = 1). The characteristics of the enrolled patients are summarized in Table 1 . KL-6 and SP-D are both secreted by type II pneumocytes. The role of both molecules has been investigated in ILD because the common pathological features of ILD include type II pneumocyte injury or remodeling. 14 KL-6 is a mucinous glycoprotein with a high molecular weight. The production of KL-6 is upregulated in regenerating type II pneumocytes and serum KL-6 has been reported to be useful as a diagnostic and prognostic biomarker in ILD. 14 SP-D is a multimeric collectin that exhibits anti-inflammatory activity and increases opsonization. 15 The concentration of serum SP-D increases as a result of translocation from the alveoli to the bloodstream caused by the impairment of the alveolar-capillary membrane. 16 Thus, the increase in serum SP-D is thought to reflect protein translocation caused by lung injury and the clinical implication of serum SP-D is also evaluated in inflammatory disorders of the lung, including ILD. 7,17 SARS-CoV-2 primarily infects Type II pneumocytes. 18 Infection with the virus is followed by cell death, resulting in lung injury. 19 The clinical implications of serum KL-6 and SP-D levels have been investigated in the abovestated context. As per reports, both serum KL-6 and SP-D levels are elevated in patients with severe COVID-19 and, therefore, these constituents are useful biomarkers of disease severity. 9, 11, 13, 20, 21 In addition to disease severity, serum KL-6 was reported to predict pulmonary fibrosis followed by infection with SARS-CoV-2 10 patients presented with respiratory failure. According to an early report, 81% of COVID-19 patients did not present with respiratory failure. 24 Thus, the population of enrolled patients with COVID-19 in this study was considered similar to the general population of patients with COVID-19. Therefore, we believe that our results can be applied in clinical practice.

In this study, the diagnostic performance of serum SP-D was superior to that of serum KL-6. A possible explanation for the superior performance of serum SP-D is that serum SP-D level was greater in bacterial pneumonia than in COVID-19 pneumonia, while serum KL-6 level was not elevated in bacterial pneumonia. This finding is consistent with a previous report. 7 Although the reason for the difference between serum KL-6 and SP-D levels in bacterial pneumonia is unknown, the difference in the mechanisms of elevation of both molecules in the blood may affect the difference between the serum levels. Bacterial pneumonia might disrupt the alveolar-capillary membrane, but it cannot cause regeneration of type II pneumocytes, at least in the early stages of the illness. Another conceivable explanation is that the production of SP-D from type II pneumocytes might be impaired by the destruction of type II pneumocytes followed by an invasion of SARS-CoV-2 because the serum SP-D level of patients with COVID-19 pneumonia was very low.

Although the median serum SP-D level of patients with COVID-19 was 24.7 (8.6-51.0) ng/ml in this study, the cut-off level of serum SP-D for distinguishing interstitial pneumonia from healthy controls is generally 110 ng/ml and the mean serum SP-D level of healthy volunteers is reported to be 40-98 ng/ml. 17 Shinji Abe: project administration; supervision.

None. This study did not receive funding from any sources.

The authors declare no conflicts of interest.

The corresponding author declares that this manuscript is honest, precise and transparent account of the study. Any aspects of the study have not been omitted.

The data analyzed in this study are available from the corresponding author on reasonable request.

The study was a retrospective study, and it was approved by the Ethics Committee of the Tokyo Medical University Hospital (approval number, T2021-0183).

COVID-19 diagnostics in context

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Pulmonary and extra-pulmonary clinical manifestations of COVID-19

Effectiveness of COVID-19 diagnosis and management tools: a review

CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients

Chest-CT mimics of COVID-19 pneumonia-a review article

Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases

Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia

Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: a longitudinal retrospective analysis

Serial KL-6 measurements in COVID-19 patients

Serum KL-6 concentrations as a novel biomarker of severe COVID-19

Exogenous pulmonary surfactant: a review focused on adjunctive therapy for severe acute respiratory syndrome coronavirus 2 including SP-A and SP-D as added clinical marker

The role of angiopoietin-2 and surfactant protein-D levels in SARS-CoV-2-related lung injury: a prospective, observational, cohort study

Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases

Surfactant protein-D and pulmonary host defense

Neither SP-A nor NH2-terminal domains of SP-A can substitute for SP-D in regulation of alveolar homeostasis

Surfactant protein D in human lung diseases

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Pathogenesis of COVID-19 from a cell biology perspective

Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019

Serum KL-6 could represent a reliable indicator of unfavourable outcome in patients with COVID-19 pneumonia

Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients

Expression of surfactant protein D distinguishes severe pandemic influenza A (H1N1) from Coronavirus Disease

Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma

Prognostic significance of a tumor marker index based on preoperative serum carcinoembryonic antigen and Krebs von den Lungen-6 levels in nonsmall cell lung cancer

Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer

Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression

Pathological significance and prognostic value of surfactant protein D in cancer

Surfactant protein D as a potential biomarker and therapeutic target in ovarian cancer

Surfactant protein D: a useful biomarker for distinguishing COVID-19 pneumonia from COVID-19 pneumonia-like diseases